Financial Comparison: Jaguar Animal Health (NASDAQ:JAGX) vs. Bausch Health Cos (NYSE:BHC)

Jaguar Animal Health (NASDAQ:JAGX) and Bausch Health Cos (NYSE:BHC) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership and risk.

Earnings & Valuation

This table compares Jaguar Animal Health and Bausch Health Cos”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jaguar Animal Health	$27.79 million	0.03	-$53.43 million	($3,731.33)	-0.00
Bausch Health Cos	$10.27 billion	0.23	$157.00 million	($2.96)	-2.16

Bausch Health Cos has higher revenue and earnings than Jaguar Animal Health. Bausch Health Cos is trading at a lower price-to-earnings ratio than Jaguar Animal Health, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Jaguar Animal Health has a beta of -0.11, indicating that its stock price is 111% less volatile than the S&P 500. Comparatively, Bausch Health Cos has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500.

Institutional & Insider Ownership

12.0% of Jaguar Animal Health shares are held by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are held by institutional investors. 0.1% of Jaguar Animal Health shares are held by company insiders. Comparatively, 20.7% of Bausch Health Cos shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Jaguar Animal Health and Bausch Health Cos’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Jaguar Animal Health	-187.88%	N/A	-131.45%
Bausch Health Cos	-10.12%	-561.95%	6.31%

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Jaguar Animal Health and Bausch Health Cos, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jaguar Animal Health	1	0	0	0	1.00
Bausch Health Cos	1	5	0	1	2.14

Bausch Health Cos has a consensus price target of $8.00, suggesting a potential upside of 25.04%. Given Bausch Health Cos’ stronger consensus rating and higher probable upside, analysts plainly believe Bausch Health Cos is more favorable than Jaguar Animal Health.

Summary

Bausch Health Cos beats Jaguar Animal Health on 12 of the 14 factors compared between the two stocks.

About Jaguar Animal Health

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

About Bausch Health Cos

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.